Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Fecal Transplant Therapy Market Growth Performance Trended Historically, And What Lies Ahead?
There has been solid growth in the fecal transplant therapy market size in the past few years. Its size will increase from $2.02 billion in 2024 to $2.15 billion in 2025, with a compound annual growth rate (CAGR) of 6.4%. The expansion during the historical period is due to the rising awareness about fecal transplant procedures, a high demand for cutting-edge treatment techniques, growing worldwide awareness, an increase in research and development funding, and a rising occurrence of inflammatory bowel disease.
What Is the Forecast for the Fecal Transplant Therapy Market Size Through 2029?
The market size for fecal transplant therapy is projected to experience substantial expansion in the coming years, with an estimated growth to $2.71 billion by 2029 at a compound annual growth rate (CAGR) of 6.0%. The boost in this forecast period can be ascribed to the growing use of biologics in treatment, heightened occurrence of chronic diseases, augmented utilization of biopesticides, escalating prescriptions of new drugs, and increasing numbers of patients with specific medical conditions. The forecast period will also see some notable trends such as an augmented attention on microbiome research, progress in the creation of synthetic alternatives, upsurge in clinical trials, advancements in delivery approaches, and an expansion in donor screening.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19431&type=smp
What are the Key Market Players in Fecal Transplant Therapy Market and How They’re Evolving?
Major companies operating in the fecal transplant therapy market are Mayo Clinic, Mount Sinai Health System Inc., Northwestern Medicine, NYU Langone Health, Michigan Medicine, UCLA Health, Duke University Health System Inc., Stanford Health Care, Ferring Pharmaceuticals, Cincinnati Children’s Hospital Medical Center, Emory Healthcare, Cambridge University Hospitals NHS Foundation Trust, Hamilton Health Sciences Corporation, Brigham and Women’s Faulkner Hospital Inc., Rebiotix Inc., Seres Therapeutics Inc., UPMC Hillman Cancer Center, OpenBiome, Center for Digestive Disease, BiomeBank Incorporated, The Regents of the University of California
What Are the Primary Growth Drivers in the Fecal Transplant Therapy Market?
The rising occurrence of inflammatory bowel disease (IBD) is anticipated to contribute to the expansion of the fecal transplant therapy markets in the future. IBD, a lasting inflammation of the gastrointestinal tract, encompasses conditions like Crohn’s disease and ulcerative colitis. Increased consumption of overly processed foods, inappropriate or frequent use of antibiotics, advancements in hygiene and a decrease in exposure to infectious agents during youth drive the growing number of inflammatory bowel disease instances. Fecal transplant therapy focuses on reverting the gut microbiota to a healthier state, thereby lowering inflammation and enhancing symptom management in those with IBD, potentially impacting its treatment and progression. For example, data predicted by non-profit organization Crohn’s and Colitis Canada in June 2023 suggest a rise to 470,000 individuals with IBD in Canada by 2035, a considerable increase from the estimated 322,600 in 2023. Consequently, the rising occurrence of inflammatory bowel disease is stimulating the expansion of the fecal transplant therapy market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=19431&type=smp
What Are the Leading Segments in the Global Fecal Transplant Therapy Industry?
The fecal transplant therapymarket covered in this report is segmented –
1) By Procedure: Fecal Enema, Fecal Bacteriotherapy, Stool Transplant, Human Probiotic Infusion, Fecal Transfusion
2) By Disease: Clostridium Difficile Infection, Autism, Obesity, Parkinson’s Disease (PD), Diabetes Mellitus, Other Diseases
3) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Fecal Enema: Retention Enema, Cleansing Enema, Retention-Based Fecal Transplants, Home Administration Kits
2) By Fecal Bacteriotherapy: Suspension-Based Bacteriotherapy, Capsule Formulations, Customized Bacterial Preparations, Single Strain vs. Multi-Strain Products
3) By Stool Transplant: Direct Stool Transplant Procedures, Stool Suspension Transplant, Stool Capsule Transplant, Automated Stool Preparation Systems
4) By Human Probiotic Infusion: Single-Strain Probiotic Infusions, Multi-Strain Probiotic Infusions, Probiotic Blends With Prebiotics, Infusion Kits for Healthcare Providers
5) By Fecal Transfusion: Intravenous Fecal Transfusion, Transfusion via Gastrostomy Tube, Pre-Packaged Fecal Transfusion Solutions, Fecal Transfusion For Research Purposes
What Are the Key Market Trends in the Fecal Transplant Therapy Industry?
Renowned corporations active in the fecal transplant therapy market are concentrating their efforts on the creation of novel therapies, such as fecal microbiota transplantation (FMT) therapy in pill form, in order to increase patient adherence and extend the reach of the treatment. This oral pill version of fecal microbiota transplantation (FMT) therapy encases living bacteria taken from donor fecal matter. The ultimate goal of this treatment is to restore a healthy balance of gut bacteria and enhance gastrointestinal health. Take the case of April 2023, when the American biotech firm, Seres Therapeutics Inc., in conjunction with Switzerland’s healthcare company, Nestlé Health Science S.A., introduced VOWST. Distributed as capsules, this offers a more convenient and less intrusive alternative for the prevention of recurrent clostridioides difficile infection (rCDI) in adults who have undergone antibacterial treatment. VOWST, as opposed to traditional fecal microbiota transplantation (FMT) that utilizes whole stools, employs live microbial spores from multiple Firmicute species, derived from the fecal microbiota of healthy human donors, with a potential to rejuvenate the gut microbiome.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/fecal-transplant-therapy-global-market-report
What Is the Regional Outlook for the Fecal Transplant Therapy Market?
North America was the largest region in the fecal transplant therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fecal transplant therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19431
This Report Delivers Insight On:
1. How big is the fecal transplant therapy market, and how is it changing globally?
2. Who are the major companies in the fecal transplant therapy market, and how are they performing?
3. What are the key opportunities and risks in the fecal transplant therapy market right now?
4. Which products or customer segments are growing the most in the fecal transplant therapy market?
5. What factors are helping or slowing down the growth of the fecal transplant therapy market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model